

Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration: A Systematic Review

Castillo, M. M., Mowatt, G., Elders, A., Lois, N., Fraser, C., Hernández, R., Amoaku, W., Burr, J. M., Lotery, A., Ramsay, C. R., & Azuara-Blanco, A. (2015). Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration: A Systematic Review. *Ophthalmology*, *122*(2), 399-406. https://doi.org/10.1016/j.ophtha.2014.07.055

Published in:

Ophthalmology

Document Version: Peer reviewed version

Queen's University Belfast - Research Portal:

Link to publication record in Queen's University Belfast Research Portal

Publisher rights

Copyright 2015 by the American Academy of Ophthalmology

This is the author's version of a work that was accepted for publication in Ophthalmology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Ophthalmology, [VOL 122, ISSUE 2, (February 2015)] doi:10.1016/j.ophtha.2014.07.055

General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. - Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Optical coherence tomography for the monitoring of neovascular

2 age-related macular degeneration: a systematic review

| Mayret M Castillo ¹ MSc, Opth | mayret.castillo@outlook.com |
|--|--|
| Graham Mowatt ¹ MA (Hons), MBA | eandg.mowatt@btinternet.com |
| Andrew Elders ^{1,2} MSc, BSc | andrew.elders@gcu.ac.uk |
| Noemi Lois ³ PhD, FRCOphth | n.lois@qub.ac.uk |
| Cynthia Fraser ¹ MA (Hons) | c.fraser@abdn.ac.uk |
| Rodolfo Hernández ^{1,4} Lic. Econ, MSC | r.a.hernandez@abdn.ac.uk |
| Winfried Amoaku ⁵ FRCOpth, PhD | Winfried.Amoaku@nottingham.ac.uk |
| Jennifer M Burr ⁶ FRCOphth, MSc | jmb28@st-andrews.ac.uk |
| Andrew Lotery ⁸ FRCOphth | A.J.Lotery@soton.ac.uk |
| Craig R Ramsay ¹ BSc (Hons), PhD | c.r.ramsay@abdn.ac.uk |
| Augusto Azuara-Blanco ² PhD, FRCOphth | a.azuara-blanco@qub.ac.uk |
| | |
| | |
| ¹ Health Services Research Unit, University of Aberdeen, UK | |
| ² Glasgow Caledonian University, UK | |
| ³ Centre for Experimental Medicine, Queen's University Belfast, UK | |
| ⁴ Health Economics Research Unit, University of Aberdeen, UK | |
| ⁵ University of Nottingham, UK | |
| ⁷ University of St Andrews, UK | |
| ⁸ University of Southampton, UK | |
| | |
| Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any | |
| 28 material discussed in this article. | |
| | Mayret M Castillo ¹ MSc, Opth Graham Mowatt ¹ MA (Hons), MBA Andrew Elders ^{1,2} MSc, BSc Noemi Lois ³ PhD, FRCOphth Cynthia Fraser ¹ MA (Hons) Rodolfo Hernández ^{1,4} Lic. Econ, MSC Winfried Amoaku ⁵ FRCOpth, PhD Jennifer M Burr ⁶ FRCOphth, MSc Andrew Lotery ⁸ FRCOphth Craig R Ramsay ¹ BSc (Hons), PhD Augusto Azuara-Blanco ² PhD, FRCOphth ¹ Health Services Research Unit, University of Aber ² Glasgow Caledonian University, UK ³ Centre for Experimental Medicine, Queen's Univer ⁴ Health Economics Research Unit, University of Aber ⁵ University of Nottingham, UK ⁷ University of St Andrews, UK ⁸ University of Southampton, UK |

30 Abstract

Topic: To compare the accuracy of Optical Coherence Tomography (OCT) with alternative
 tests for monitoring neovascular age-related macular degeneration (nAMD) and detecting
 disease activity among eyes previously treated for this condition

Clinical Relevance: Traditionally FFA has been considered the reference standard to
 detect nAMD activity but FFA is costly and invasive. Replacement of FFA by OCT can be
 justified if there is a substantial agreement between tests.

Methods: Systematic review and meta-analysis. Index test: OCT. Comparator tests: visual acuity, clinical evaluation (slit lamp), Amsler chart, colour fundus photographs, infra-red reflectance, red-free images/blue reflectance, fundus autofluorescence imaging (FAF), indocyanine green angiography (ICGA), preferential hyperacuity perimetry (PHP) and microperimetry. We searched the following databases: MEDLINE, MEDLINE In Process, EMBASE, Biosis, SCI, the Cochrane Library, DARE, MEDION and HTA database, last literature search: March 2013. We used QUADAS-2 to assess risk of bias.

44 Results: We included eight studies involving over 400 participants. Seven reported the performance of OCT (three TD-OCT, three SD-OCT, one both types) and one the 45 performance of ICGA in the detection of nAMD activity. We did not find studies directly 46 comparing tests in the same population. The pooled sensitivity and specificity (95% CI) of 47 TD-OCT and SD-OCT for detecting active nAMD was 85% (72% to 93%) and 48% (30% to 48 67%), respectively. One study reported ICGA, with sensitivity of 75.9% and specificity of 49 88.0% for the detection of active nAMD. Half of the studies were considered to have high 50 51 risk of bias.

52 Conclusions: There is a substantial disagreement between OCT and FFA findings in
53 detecting active disease in patients with nAMD who are being monitored. Both modalities
54 may be needed to comprehensively monitor patients with nAMD.

55 Introduction

Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment 56 57 of neovascular age-related macular degeneration (nAMD). Visual outcomes following anti-VEGF therapy¹⁻⁴ have been unparalleled by previous therapies which included laser 58 photocoagulation⁵⁻⁶ and photodynamic therapy.⁷ The effectiveness of anti-VEGF drugs 59 depends, however, on frequent monitoring and early diagnosis of reactivation of the 60 condition. "Fundus fluorescein angiography (FFA) interpreted by an ophthalmologist was in 61 the recent past the reference standard for the detection of active nAMD among those eyes 62 already treated^{8,9} as it directly detects the presence of the active neovascularisation. 63 However, FFA is an invasive and a time-consuming test with, although rare, potentially 64 serious side effects. Other alternative monitoring technologies are available of which the 65 most widely used is optical coherence tomography (OCT)." 66

OCT, including time-domain (TD-OCT) and the most recently developed spectral-domain (SD-OCT), is a light-wave based technology that allows the imaging of the retina and choroid, obtaining "sections" through areas with neovascularisation and surrounding tissues. Scan rates and resolution parameters have greatly improved over the last decade and continue to develop. OCT is a non-invasive, non-contact test typically undertaken by trained medical photographers or technicians and interpreted by ophthalmologists. If OCT were to be able to accurately detect the re-activation of nAMD then FFA would not be needed.

The aim of this study was to evaluate the accuracy, interpretability and acceptability of OCT alone or in combination with other tests compared with clinical evaluation of FFA for the detection of active disease in patients with nAMD under treatment and surveillance.

77

78

80 Methods

The target condition was nAMD of any phenotype. Eligible participants were individuals who had been previously treated for nAMD with any type of treatment, and who were monitored to detect active disease. Thus, patients could have active or stable neovascular disease

84 "The index test was OCT, alone or in combination with other tests, i.e., we included studies 85 that used OCT alone or associated with other test or tests to detect nAMD disease activity, including any of the following: clinical evaluation with slit lamp biomicroscopy, visual acuity, 86 87 Amsler grid, colour fundus photography, infra-red reflectance, red-free images, fundus 88 autofluorescence imaging (FAF), indocyanine green angiography (ICGA), preferential 89 hyperacuity perimetry (PHP) and microperimetry. The reference standard was FFA. 90 Participants were individuals with known, treated nAMD, with any type of treatment, and who 91 were monitored for the condition to detect active disease. We considered direct (head-to-92 head) comparisons in which all participants received the index test, comparator test(s) and 93 the reference standard; indirect comparisons (e.g. case control studies) in which estimates 94 of the accuracy of the respective tests were obtained in different study groups, and randomised controlled trials evaluating effectiveness outcomes where e.g. treatment was 95 based on OCT compared with FFA findings. We also included studies evaluating the 96 97 acceptability and/or interpretability of the tests.

98 We identified published, unpublished and ongoing studies from searches of electronic 99 databases (from 1995 to March 2013) and appropriate websites. There were no language 100 restrictions. We searched MEDLINE, MEDLINE In-Process, EMBASE, Biosis and Science Citation Index (SCI) for all reviews. We searched the Cochrane Central Register of 101 Controlled Trials (CENTRAL) for additional reports of RCTs reporting effectiveness 102 outcomes and PsycINFO and ASSIA for studies reporting acceptability data. The Cochrane 103 database of Systematic Reviews (CDSR), Database of Abstracts of reviews of Effects 104 (DARE), MEDION and HTA database were searched for relevant systematic reviews and 105

106 HTA reports. We searched abstracts and presentations from recent conferences (from January 2009 to September 2012) of the Academy of Ophthalmology (AAO), the Association 107 for Research in Vision and Ophthalmology (ARVO), and the European Association for Vision 108 and Eye Research (EVER) and also the WHO International Clinical Trials Registry Platform 109 110 (ICTRP), Clinical Trials.gov and EU Clinical Trials Register for ongoing studies. Websites of key journals, professional organisations and manufacturers of equipment were also 111 112 consulted. We also evaluated reference lists of all included studies for possible inclusion 113 and we contacted authors for details of additional potentially relevant reports.

Two reviewers independently screened the titles and abstracts (if available) of all reports 114 identified by electronic searches. We obtained full-text copies of all potentially relevant 115 papers and two reviewers independently assessed them for inclusion. Two reviewers 116 independently assessed the risk of bias and applicability concerns of included full-text 117 studies, using an adapted version of the updated quality assessment of diagnostic accuracy 118 studies (QUADAS-2) checklist.¹⁰ The QUADAS-2 checklist is designed to be adapted to the 119 120 specific review topic. The investigators resolved disagreements by consensus or arbitration by a third reviewer. QUADAS-2 consists of four key domains covering (1) patient selection, 121 (2) index test, (3) reference standard, and (4) flow of patients through the study and timing of 122 123 the index test(s) and reference standard. Each domain is assessed in terms of the risk of 124 bias. The first three domains are also assessed for concerns regarding their applicability in 125 terms of whether (i) the participants and setting, (ii) index test, its conduct or interpretation 126 and (iii) target condition as defined by the reference standard match the question being addressed by the review. Within each domain signaling questions are included to assist in 127 making a judgment about the risk of bias, with the standard tool containing 11 such 128 129 questions across the four domains.

QUADAS-2 was designed to be adaptable to a specific review topic. For this review,
QUADAS-2 was modified by adding an additional signaling question to domain 1 (patient
selection) to assess whether participant pre-selection had been avoided. Domains 2 (index

133 test), 3 (reference standard) and 4 (flow and timing) were retained in their entirety. Therefore the modified tool contained 12 signaling questions, with each worded so that a 134 rating of 'Yes' was always optimal in terms of methodological quality. If any signaling 135 questions within a domain were rated 'No' then that domain was judged to be at high risk of 136 137 bias. With regard to question 9 in the modified tool (appropriateness of the time interval between the index test and the reference standard), it was agreed that to be considered 138 appropriate, the time interval between the index test and reference standard should be no 139 longer than one week." 140

Regarding the statistical analysis we calculated sensitivity and specificity of individual 141 studies when possible. Where two or more studies reported sufficient data we planned to 142 create summary receiver operating characteristic (SROC) curves. We intended to fit meta-143 analysis models using the hierarchical summary receiver operating characteristic (HSROC) 144 model¹¹ with the SAS software (version 9.1) when possible. We used a symmetric SROC 145 model, as it allows estimation of random effects for the threshold and accuracy effects 146 147 accounting for the active and non-active sample sizes in each study. We arranged to produce the SROC curves from the HSROC models on the corresponding SROC plots. We 148 planned to report a point estimate and 95% confidence interval (CI) for each model for the 149 150 summary sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds 151 ratios (DORs).

152

153 Results

We identified 4682 titles and abstracts, of which 179 reports were evaluated in full-text
(Figure 1). Eight^{12,13,14,15,16,17,18,19} were monitoring studies involving people previously
diagnosed with nAMD and under follow-up surveillance; one study, by Salinas-Alaman et
al.,¹⁷ reported results for both diagnosis and monitoring (Table 1). No studies evaluated the
performance of OCT associated with other test(s).

Of the eight included studies, four were prospective,^{15,16,17,19} three were retrospective^{12,13,14} while in the study by van de Moere et al.¹⁸ this information was not reported. In five studies the participants were a consecutive sample.^{13,14,16,17,19} The eight studies enrolled 463 participants.

Four studies were judged to be high risk of bias for reasons such as inappropriate exclusions and pre-selection of participants, length of time between the index test and the reference standard, and not all participants being included in the analysis (Figure 2). All of the monitoring studies were judged to be applicable to our study question.

Some studies reported the "eye "as the unit of analysis, i.e., only data of a single 167 examination/comparison of an eye at one point in time was included in the study. Other 168 studies reported an "examination" as the unit of analysis, i.e., a patient or eye was examined 169 several times over a period of time, and the authors included data of several examinations of 170 171 the same patient and eye. Of the seven studies reporting OCT, five used the eye as the unit of analysis (number of eyes analysed = 363);^{12,13,14,18,19} in four of these one eye per patient 172 was analysed (n = 304 eyes).^{13,14,18,19} Two studies reported examination as the unit of 173 analysis (both TD-OCT).^{15,17} Two studies reported detection of classic and occult CNV;¹⁴ 174 pigment epithelial detachment (PED) and cystoid macular oedema.¹⁸ The studies by 175 Henschel et al.¹⁵ and van de Moere et al.¹⁸ also reported the performance of OCT in 176 detecting intraretinal and subretinal fluid. 177

In two studies^{12,14} the participants had received anti-vascular endothelial growth factor (anti VEGF) therapy while in five^{13,15,17,18,19} the treatment was photodynamic therapy (PDT). In the
 study reporting ICGA¹⁶ the participants had received laser photocoagulation.

The median (range) prevalence of active nAMD across five studies where this information
was available at participant level was 57.9% (49.2% to 83.3%).^{12,13,14,18,19}

183 Three TD-OCT studies^{12,13,19} and two SD-OCT reports,^{12,14} with the eye as the unit of 184 analysis, reported both sensitivity and specificity, providing sufficient data for inclusion in a

185 meta-analysis. Figure 3 shows forest plots of the sensitivity and specificity of the individual studies and SROC curves for (a) all OCT studies, (b) the three TD-OCT studies and (c) the 186 two SD-OCT studies, respectively. Table 2 shows the pooled estimates for these studies. 187 For all OCT studies, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) 188 and 48% (30% to 67%) respectively. For TD-OCT, the pooled sensitivity and specificity 189 (95% CI) was 70% (56% to 80%) and 65% (48% to 79%). For TD-OCT and the group of all 190 four OCT studies the likelihood ratio and DOR values reported were below the level 191 suggestive of strong evidence. It was not possible to calculate pooled estimates for the two 192 SD-OCT studies due to insufficient data. These studies reported sensitivities of 94%¹⁴ and 193 90%¹² and specificities of 27%¹⁴ and 47%,¹² which suggests that SD-OCT has higher 194 sensitivity than TD-OCT but lower specificity. 195

Two studies used examination as the unit of analysis. Henschel et al.,¹⁵ in an analysis of 61 pairs of TD-OCT and FFA examinations from 14 patients, reported sensitivity of 96.8% and specificity of 36.7% for CNV based on detection of intraretinal and/or subretinal fluid. Salinas-Alaman et al.,¹⁷ in an analysis of 176 pairs of TD-OCT and FFA examinations (number of patients not stated), reported sensitivity of 95.7% and specificity of 59.0% based on detection of intraretinal or subretinal fluid.

Four studies^{12,14,15,18} reported the sensitivity of OCT in detecting active nAMD phenotypes or 202 203 active nAMD based on detection of intraretinal/subretinal fluid (see Table 3). The study by Giani et al.¹⁴ reported high sensitivity for the detection by SD-OCT of both classic and occult 204 CNV activity (90.9% and 100% respectively). In the studies by Henschel et al.¹⁵ (unit of 205 analysis: examination) and van de Moere et al.¹⁸ (unit of analysis: eye) sensitivity was higher 206 for nAMD activity based on detection of intraretinal fluid (90.3% and 82.9% respectively) 207 compared with subretinal fluid (71.0% and 47.1% respectively). Van de Moere et al.¹⁸ also 208 reported sensitivity of TD-OCT for detection of cystoid macular oedema and pigment 209 210 epithelial detachment, both low at 22.9% and 5.7% respectively. In the study by Khurana et

al¹² the sensitivity of SD-OCT was higher than that of TD-OCT for nAMD activity based on
the detection of intraretinal fluid, retinal cystoid abnormalities or subretinal fluid.

One study, by Khurana et al.,¹² compared TD-OCT with SD-OCT in an analysis of 59 eyes of 56 participants. Although sensitivity was considerably higher for SD-OCT than for TD-OCT (89.7% versus 58.6%), specificity was lower (46.7% versus 63.3%).

One study, by Regillo et al.,¹⁶ in an analysis of 54 pairs of indocyanine green angiograms compared with fluorescein angiograms, obtained from 24 eyes of 21 patients, reported sensitivity of 75.9% and specificity of 88.0% in detecting nAMD activity.

219 No studies were identified that met our inclusion criteria providing information on clinical effectiveness outcomes (e.g. visual acuity) when treatment was based on OCT compared 220 with FFA findings. Only one monitoring study, by van de Moere et al.,¹⁸ reported 221 222 information relating to the interpretability of the tests. This TD-OCT study reported that, of 136 participants enrolled, 17 (12.5%) were excluded from the analysis due to the poor 223 quality of the OCT or FFA images. The study did not specify how many of these poor quality 224 images were OCT images and how many were FFA. No studies were identified that met our 225 inclusion criteria reporting the acceptability of the tests, either to those providing the tests or 226 to those receiving them. 227

228

229 Discussion

Due to the burden of nAMD to patients and health care providers, an effective and efficient monitoring strategy to detect active disease is needed. The use of frequent (monthly or two-monthly) FFA is not recommended. FFA is hampered by its cost, the fact that it is a relatively time-consuming invasive imaging technology and, although rare, possible risks. Current Preferred Practice Patters by the AAO advise the use of FFA"depending on the clinical findings and judgement of the treating ophthalmologist".⁹ OCT is now routinely used for monitoring eyes with nAMD previously treated.

We identified a relatively small body of evidence comparing OCT against a reference standard of FFA for the diagnosis of active nAMD in patients under surveillance and treated for this condition. We included eight monitoring studies (all full-text) involving over 400 participants. Seven reported the performance of OCT (five TD-OCT, one SD-OCT, one both types) and one the performance of ICGA in the detection of nAMD activity.

To compare the performance of diagnostic tests ideally direct comparisons of the accuracy 242 243 of different tests applied to the same population would be most informative. Alternatively it is possible to evaluate studies of different tests applied to different populations against a 244 common reference standard, using models to indirectly compare tests. In this review four of 245 the OCT studies provided sufficient data for inclusion in a meta-analysis. The pooled 246 247 sensitivity (95% CI) for all OCT was moderately high at 85% (72% to 93%) but with low specificity at 48% (30% to 67%). For TD-OCT, the pooled sensitivity and specificity was 248 moderate at 70% (56% to 80%) and 65% (48% to 79%) respectively. It was not possible to 249 calculate pooled estimates for the two SD-OCT studies using hierarchical summary receiver 250 251 operating characteristic (HSROC) methodology due to insufficient data. These studies reported sensitivities of 94%¹⁴ and 90%¹² and specificities of 27%¹⁴ and 47%.¹² Other than 252 OCT, one study reported ICGA, with sensitivity of 75.9% and specificity of 88.0% for the 253 detection of active nAMD. We did not find other studies reporting the performance of 254 255 alternative technologies.

This study suggests that SD-OCT may be more sensitive but less specific in detecting active 256 257 nAMD than TD-OCT. It is likely that SD-OCT can detect small amounts of fluid in the retina (due to its high resolution) better than TD-OCT. However, fluid does not always indicate 258 active CNV but may indicate RPE malfunctioning, for instance related to RPE atrophy, which 259 has now been recognised to occur frequently in eyes with nAMD undergoing anti-VEGF 260 therapies.^{2, 3, 20, 21} Some of the observed heterogeneity among studies results can be 261 explained by the different populations, phenotypes, proportion of active cases, type of 262 treatment, and methodological quality. 263

In terms of strengths of this study, a comprehensive literature search was undertaken and both English and non-English language studies were included. We assessed risk of bias using a modified version of the QUADAS-2 questionnaire, tailored to the needs of this review. We used a robust method, HSROC model, for the analysis, which takes account of the trade-off between true/false positives and models between-study heterogeneity.²²

The reference standard test used for this review was FFA interpreted by an ophthalmologist, 269 270 and therefore was assumed to have perfect sensitivity and specificity. Consequently it was not possible to address the question of whether OCT might actually be a better test than 271 FFA and have higher sensitivity or specificity than the current reference standard. One 272 approach that has been suggested for determining when a new test should replace the 273 reference standard is that proposed by Glasziou et al.²³ Glasziou et al. suggested the use of 274 a third, 'fair umpire' test, which although potentially less accurate than either the new test or 275 the reference standard, could be considered nonetheless a fair umpire test if its errors were 276 independent of the other tests.²³ However, the authors acknowledged that this would usually 277 278 be difficult to demonstrate. Unfortunately, none of the included OCT studies involving a third 279 test provided a sufficient level of detail to allow us to explore this approach.

The false positive rate of OCT was high. A few studies suggested possible explanations for their false positive results. Subretinal or intraretinal fluid, readily detected by OCT, especially by SD-OCT, may not necessarily indicate active neovascular AMD and may be seen over disciform scars and even atrophic areas.²⁴ If the diagnosis of active nAMD is established by the presence of fluid on OCT false positives could, thus, be made, leading to unnecessary treatments. Similar lack of agreement between OCT and FFA to diagnose nAMD in high risk eyes have been observed by Do et al.²⁵

The clinical implications of this review are potentially important as we found evidence of substantial lack of agreement between OCT and FFA to determine activity of nAMD lesions. There are also potential implications regarding the interpretation of results of landmark studies that have used only OCT to guide decisions to treat nAMD, such as the prn arms of

the CATT study² and the HARBOR study.²⁶ It is possible the differences in efficacy between
monthly and prn arms might be explained in part by a sub-optimal of diagnostic accuracy of
OCT to detect active nAMD.

In conclusion, our review identified a relatively small number of studies, of variable quality, on the performance of OCT in the monitoring of people with treated nAMD under surveillance to detect disease activity. The available evidence suggests that although OCT is a sensitive test for detecting reactivation of nAMD, it has poor specificity. Consequently, it is not recommended that OCT is used alone to detect reactivation of nAMD in patients under surveillance. According to current evidence OCT should not replace the reference standard of FFA for monitoring patients with nAMD.

301 Acknowledgements

This paper was based on a wider piece of research that was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) Programme (project number 10/57/22) that will be published in full in Health Technology Assessment. The Health Services Research Unit is core-funded by the Chief Scientist Office (CSO) of the Scottish Government Health and Social Care Directorates. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, Department of Health or the CSO.

310 **References**

- 311 1 Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin
- 312 photodynamic therapy for neovascular age-related macular degeneration: Two-year

results of the ANCHOR study. Ophthalmology 2009;116:57-65.

- Martin DF, Maguire MG, Fine SL, et al., Comparison of Age-related Macular
- 315 Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and
- 316 bevacizumab for treatment of neovascular age-related macular degeneration: two-
- 317 year results. Ophthalmology 2012;119:1388-98.
- 318 3 Chakravarthy U, Harding SP, Rogers CA, et al., the IVAN Study Investigators.
- 319 Ranibizumab versus bevacizumab to treat neovascular age-related macular
- degeneration: one-year findings from the IVAN randomized trial. Ophthalmology
 2012;119:1399-411.
- ____,.....
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related
 macular degeneration. N Engl J Med 2006;355:1419-31.
- Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal
 neovascular lesions in age-related macular degeneration. Results of a randomized
 clinical trial.. Arch Ophthalmol 1991;109:1220-31.
- Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal
 choroidal neovascularization. Five-year results from randomized clinical trials.. Arch
 Ophthalmol 1994;112:500-9.
- 330 7 Treatment of age-related macular degeneration with photodynamic therapy (TAP)
- 331 Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in
- 332 age-related macular degeneration with verteporfin: one-year results of 2 randomized

clinical trials--TAP report.. Arch Ophthalmol 1999;117:1329-45.

Age-related macular degeneration - Guidelines for management [document on the
 Internet]. London: Royal College of Ophthalmologists; 2009 [accessed September

336

2013]. URL:

http://www.rcophth.ac.uk/core/core_picker/download.asp?id=1185&filetitle=Age%. 337 9 Amercian Academy of Ophthalmology Retina Panel. Preferred Practice Pattern 338 Guidelines: Age-Related Macular Degeneration. San Fransisco: American Academy 339 340 of Ophthalmology; 2011 [accessed September 2013]. URL:http://www.aao.org/ppp. Whiting PF, Ruties AW, Westwood ME, et al. QUADAS-2: a revised tool for the 341 10 quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. 342 343 11 Mowatt G, Azuara-Blanco A, Burr H, Clark D, Hernandez R, Lois, Ramsay C. Systematic review and economic modelling of optical coherence tomography (OCT) 344 for the diagnosis, monitoring and guiding of treatment for neovascular age-related 345 346 macular degeneration. NIHR HTA protocol 10/57/22. http://www.nets.nihr.ac.uk/projects/hta/105722 347 348 12 Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal 349 350 neovascularization. Ophthalmology 2010;117:1376-80. 351 13 Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence 352 tomography for patients with choroidal neovascularization after photodynamic therapy. Retina 2005;25:691-6. 353 14 Giani A, Luiselli C, Esmaili DD, Salvetti P, Cigada M, Miller JW et al. Spectral-domain 354 optical coherence tomography as an indicator of fluorescein angiography leakage 355 from choroidal neovascularization. Invest Ophthalmol Vis Sci 2011;52:5579-86. 356 15 Henschel A, Spital G, Lommatzsch A, Pauleikhoff D. Optical coherence tomography 357 in neovascular age related macular degeneration compared to fluorescein 358 angiography and visual acuity. Eur J Ophthalmol 2009;19:831-5. 359 16 Regillo CD, Blade KA, Custis PH, O'Connell SR. Evaluating persistent and recurrent 360 choroidal neovascularization. The role of indocyanine green angiography. 361 Ophthalmology 1998;105:1821-6. 362

- 363 17 Salinas-Alaman A, Garcia-Layana A, Maldonado MJ, Sainz-Gomez C, Alvarez-Vidal A. Using optical coherence tomography to monitor photodynamic therapy in age 364 related macular degeneration. Am J Ophthalmol 2005;140:23-8. 365 van de Moere A, Sandhu SS, Talks SJ. Correlation of optical coherence tomography 366 18 367 and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes. Br J Ophthalmol 2006;90:304-6. 368 van Velthoven ME, Schlingemann RO, Magnani M, Verbraak FD. Added value of 369 19 370 OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT. Graefes Arch Clin Exp Ophthalmol 2006;244:1119-371 23. 372 Lois N, McBain V, Abdelkader E, Scott NW, Kumari R. Retinal pigment epithelial 373 20 atrophy in patients with exudative age-related macular degeneration undergoing 374 375 anti-vascular endothelial growth factor therapy. Retina. 2013;33:13-22. 21 McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal 376 377 angiomatous proliferation. Retina. 2011;31:1043-52. : 378 22 Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test 379 accuracy. Ann Intern Med 2008;149:889-97. 380 23 Glasziou P, Irwig L, Deeks JJ. When should a new test become the current reference standard? Ann Intern Med 2008;149:816-22. 381 382 24 Cohen SY, Dubois L, Nghiem-Buffet S, Ayrault S, Fajnkuchen F, Guiberteau B, Delahaye-Mazza C, Quentel G, Tadayoni R. Retinal pseudocysts in age-related 383 geographic atrophy. Am J Ophthalmol. 2010;150:211-217 384 25. Do DV, Gower EW, Cassard SD, et al. Detection of new-onset choroidal 385 neovascularization using optical coherence tomography: the AMD DOC Study 386 Ophthalmology 2012; 119:771-778. 387 26. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-month efficacy 388
- and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular
- age-related macular degeneration. Ophthalmology. 2013; 120:1046-1056.

391 Figure legend

392

Figure 1. Flow diagram outlining the screening and selection process of articles